Table 2.
Variable | Pre-TX |
Post-TX |
6-mo FU |
12-mo FU |
Pre-post × Condition |
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
M | (SD) | M | (SD) | M | (SD) | M | (SD) | Δ | df | F | p | Cohen's d | |
SE (%) | 1 | 9.98 | 0.003 | 1.16 | |||||||||
SR+HW | 70.66 | (11.77) | 87.77 | (7.00) | 88.07 | (7.81) | 86.62 | (9.58) | 17.11 | ||||
SHE | 70.50 | (10.12) | 75.98 | (11.50) | 5.48 | ||||||||
TST (min) | 1 | 2.50 | 0.122 | ||||||||||
SR+HW | 346.72 | (62.98) | 339.46 | (57.60) | 395.41 | (43.64) | 390.71 | (51.33) | −7.26 | ||||
SHE | 320.67 | (57.65) | 343.80 | (69.50) | 23.13 | ||||||||
SOL (min) | 1 | 5.17 | 0.029 | 0.56 | |||||||||
SR+HW | 57.60 | (33.28) | 23.18 | (22.98) | 22.28 | (20.55) | 23.24 | (19.08) | −34.42 | ||||
SHE | 56.36 | (33.85) | 40.18 | (31.76) | −16.18 | ||||||||
WASO (min) | 1 | 4.02 | 0.052 | 0.57 | |||||||||
SR+HW | 56.17 | (32.87) | 14.96 | (8.66) | 22.37 | (15.82) | 26.92 | (30.27) | −41.21 | ||||
SHE | 49.97 | (32.89) | 30.08 | (23.95) | −19.89 | ||||||||
TWAK (min) | 1 | 13.29 | 0.001 | 1.06 | |||||||||
SR+HW | 38.83 | (29.95) | 10.96 | (11.00) | 16.71 | (16.71) | 22.97 | (15.99) | −27.87 | ||||
SHE | 40.74 | (34.53) | 43.50 | (43.00) | 2.76 | ||||||||
Drugs (doses/wk) | 1 | 19.48 | < 0.001 | 1.05 | |||||||||
SR+HW | 1.25 | (0.90) | 0.28 | (0.45) | 0.17 | (0.34) | 0.18 | (0.35) | −0.97 | ||||
SHE | 1.13 | (0.86) | 1.11 | (0.93) | −0.02 |
All effect size calculations were performed with conventions from the ES software package using Data Source 0801: Two-Factor (conditions × Time) repeated-measures ANOVA.
TX, treatment; FU, follow-up; SR+HW, sleep restriction therapy and hypnotic withdrawal condition; SHE, sleep hygiene education condition; SOL, sleep onset latency; WASO, wake time after sleep onset; TWAK, final wakefulness (amount of awake time between the final awakening and the time of getting out of bed); SE, sleep efficiency; TST, total sleep time.